시신경 척수염 신규 치료법 : 2026년 2분기

The Global Neuromyelitis Optica Emerging Therapies Market is projected to grow at a CAGR of 10.1% during the forecast period, increasing from USD 61.27 million in 2026 to USD 145.84 million by 2035.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune disease of the central nervous system characterized by recurrent inflammatory attacks affecting the optic nerves, spinal cord, and brainstem. The disease is primarily associated with aquaporin-4 (AQP4) autoantibodies, although a subset of patients is associated with myelin oligodendrocyte glycoprotein (MOG) antibodies or remains seronegative. Historically, treatment relied on broad immunosuppressive therapies; however, advances in immunology have led to the development of highly targeted biologics that significantly improve relapse prevention and long-term neurological outcomes. Emerging therapies analysis has become increasingly important for pharmaceutical companies, biotechnology firms, investors, healthcare providers, and research organizations seeking to evaluate future therapeutic opportunities and competitive positioning.

Emerging therapies analysis provides comprehensive insights into investigational drugs, clinical development progress, novel mechanisms of action, regulatory milestones, licensing activities, strategic collaborations, and commercialization potential. As research activity accelerates, this analysis supports informed decision-making across research and development, portfolio management, licensing, and investment planning.

Market Drivers

Expanding Development of Targeted Immunotherapies

One of the primary drivers of market growth is the rapid development of targeted immunotherapies designed to interrupt the specific immune pathways responsible for NMOSD. New biologic therapies targeting complement proteins, B cells, interleukin-6 (IL-6), and other immune mediators are demonstrating promising clinical outcomes and transforming disease management.

Increasing Clinical Research Activity

Clinical development activity has expanded significantly as pharmaceutical and biotechnology companies continue to invest in innovative therapies capable of reducing relapse frequency, preventing disability progression, and improving quality of life. Recent analyses show a rapidly growing global clinical trial landscape, with increasing numbers of early- and late-stage development programs.

Growing Investment in Rare Diseases

Rare neurological diseases have become a strategic priority for the pharmaceutical industry. Regulatory incentives such as orphan drug designation, accelerated approval pathways, and market exclusivity are encouraging greater investment in NMOSD drug development and supporting a highly active innovation environment.

Advances in Precision Medicine

Improved understanding of disease biology, biomarkers, and antibody status is enabling the development of personalized therapeutic approaches. Precision medicine strategies are improving patient selection, optimizing clinical trial design, and supporting the development of therapies tailored to specific patient populations.

Market Restraints

Limited Patient Population

As a rare autoimmune disorder, NMOSD affects a relatively small patient population worldwide, making patient recruitment for clinical trials challenging and extending development timelines.

High Research and Development Costs

The development of biologics, monoclonal antibodies, and advanced immunotherapies requires substantial investment in research, manufacturing, regulatory compliance, and long-term safety monitoring.

Complex Clinical Trial Design

Clinical studies often require extended follow-up periods to evaluate relapse prevention, disability progression, safety, and durability of treatment response, increasing operational complexity and development costs.

Technology and Emerging Therapy Insights

The global NMOSD emerging therapies market can be segmented by development phase, therapeutic modality, mechanism of action, molecule type, and route of administration.

By development phase, the market includes discovery-stage candidates, preclinical assets, Phase I studies, Phase II trials, Phase III programs, regulatory-stage therapies, and lifecycle management initiatives. Recent analyses indicate strong growth across both early-stage innovation and advanced clinical development, reflecting a healthy and diversified pipeline.

By therapeutic modality, the market includes monoclonal antibodies, complement inhibitors, B-cell depletion therapies, IL-6 receptor inhibitors, BTK inhibitors, FcRn inhibitors, stem cell therapies, gene therapies, and other novel immunomodulatory agents. Monoclonal antibodies continue to dominate the emerging therapy landscape due to their demonstrated efficacy in relapse prevention.

By mechanism of action, emerging therapies focus on:

• B-cell depletion
• Complement C5 inhibition
• IL-6 receptor blockade
• Bruton tyrosine kinase (BTK) inhibition
• FcRn inhibition
• Immune tolerance induction
• Cytokine modulation
• Neuroprotection and remyelination strategies

Pipeline activity is increasingly expanding beyond established targets toward innovative mechanisms that may further improve disease control and reduce long-term disability.

By molecule type, the market includes biologics, monoclonal antibodies, recombinant proteins, peptides, cell therapies, gene therapies, and small-molecule therapeutics. Advances in biotechnology and immunology continue to diversify the therapeutic pipeline.

Technological innovations including artificial intelligence-assisted drug discovery, biomarker-guided development, genomic analytics, digital health technologies, and real-world evidence platforms are improving research productivity and accelerating clinical development.

Competitive Landscape

The NMOSD emerging therapies landscape is characterized by strong participation from global pharmaceutical companies, biotechnology innovators, academic institutions, and specialized rare disease developers.

Leading companies are developing next-generation therapies targeting immune pathways involved in NMOSD pathogenesis. Current research focuses on improving efficacy, extending treatment durability, reducing relapse risk, enhancing safety profiles, and expanding treatment options for both AQP4-positive and seronegative patient populations. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships continue to strengthen research capabilities and accelerate pipeline advancement.

Future Outlook

The future NMOSD emerging therapies market is expected to be driven by continued innovation in targeted biologics, precision medicine, biomarker-based treatment selection, and novel immune-modulating therapies. Emerging treatment strategies are expected to provide improved relapse prevention, better long-term neurological outcomes, enhanced convenience, and broader treatment eligibility.

Artificial intelligence, genomic medicine, digital biomarkers, and real-world evidence platforms are expected to optimize clinical development and support faster regulatory approvals. As additional investigational therapies progress through late-stage clinical trials, the treatment landscape is expected to become increasingly competitive and diversified.

Conclusion

The global Neuromyelitis Optica emerging therapies analysis market is poised for strong growth through 2035, supported by expanding clinical research, increasing investment in rare neurological disorders, rapid advancements in targeted immunotherapies, and growing adoption of precision medicine. While challenges related to patient recruitment, high development costs, and complex clinical trial requirements remain, continued innovation across biologics, complement inhibitors, B-cell therapies, BTK inhibitors, and next-generation immunomodulators is expected to transform the future of NMOSD treatment. As more investigational therapies advance toward commercialization, the market is likely to witness significant improvements in disease management, relapse prevention, and long-term patient outcomes.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of emerging NMOSD therapies, pipeline assets, and clinical development trends.
• Competitive Landscape: Understand key developers, innovative treatment approaches, and strategic industry activities.
• Market Drivers and Future Trends: Assess technological innovations and growth opportunities shaping future therapy development.
• Actionable Recommendations: Support licensing strategies, investment decisions, pipeline prioritization, and commercialization planning.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, investors, researchers, consultants, and healthcare stakeholders.

What Businesses Use Our Reports For

Pipeline benchmarking, emerging therapy assessment, clinical trial monitoring, competitive intelligence, licensing evaluations, partnership analysis, investment planning, regulatory strategy development, and market opportunity identification.

Report Coverage

• Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
• Emerging therapy analysis by development phase, therapeutic modality, mechanism of action, and molecule type
• Clinical development trends, regulatory progress, and pipeline maturity assessment
• Competitive intelligence, company profiling, licensing activities, and strategic collaborations
• Future innovation trends, commercialization opportunities, and long-term market outlook.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Epidemiology Highlights
• 1.4 Approved Therapy Landscape
• 1.5 Emerging Pipeline Overview
• 1.6 Market Outlook and Growth Opportunities
• 1.7 Strategic Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Disease Overview
  • 2.1.1 Definition of Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • 2.1.2 Disease Classification
  • 2.1.3 Pathophysiology
  • 2.1.4 Immunological Mechanisms
  • 2.1.5 Risk Factors and Triggers
• 2.2 Disease Burden
  • 2.2.1 Global Prevalence
  • 2.2.2 Global Incidence
  • 2.2.3 Mortality and Disability Burden
  • 2.2.4 Economic Burden
• 2.3 Epidemiology Segmentation
  • 2.3.1 By Age Group
  • 2.3.2 By Gender
  • 2.3.3 By Serostatus
    • 2.3.3.1 AQP4-IgG Positive NMOSD
    • 2.3.3.2 AQP4-IgG Negative NMOSD
    • 2.3.3.3 MOG Antibody Associated Disease (Differential Epidemiology)
  • 2.3.4 By Disease Course
    • 2.3.4.1 Relapsing NMOSD
    • 2.3.4.2 Monophasic NMOSD
• 2.4 Unmet Clinical Needs
  • 2.4.1 Diagnostic Challenges
  • 2.4.2 Relapse Prevention Needs
  • 2.4.3 Long-Term Safety Concerns
  • 2.4.4 Treatment Accessibility Issues

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Disease Awareness
  • 3.1.2 Increasing Diagnosis Rates
  • 3.1.3 Expansion of Targeted Biologics
  • 3.1.4 Growing Rare Disease Funding
• 3.2 Market Restraints
  • 3.2.1 High Cost of Biologics
  • 3.2.2 Limited Patient Population
  • 3.2.3 Reimbursement Challenges
  • 3.2.4 Safety and Monitoring Requirements
• 3.3 Market Opportunities
  • 3.3.1 Novel Mechanisms of Action
  • 3.3.2 Expansion into Earlier Treatment Lines
  • 3.3.3 Emerging Markets Penetration
  • 3.3.4 Precision Medicine Approaches
• 3.4 Market Challenges
  • 3.4.1 Competitive Pipeline Environment
  • 3.4.2 Clinical Trial Recruitment Challenges
  • 3.4.3 Regulatory Complexity

4. Commercial & Market Access

• 4.1 Pricing Analysis
• 4.2 Reimbursement Landscape
• 4.3 Market Access Challenges
• 4.4 Payer Perspectives
• 4.5 Rare Disease Incentives
• 4.6 Patient Assistance Programs
• 4.7 Commercialization Strategies

5. Innovation & Pipeline Landscape

• 5.1 Pipeline Overview
• 5.2 Pipeline Segmentation by Clinical Phase
  • 5.2.1 Phase I
  • 5.2.2 Phase II
  • 5.2.3 Phase III
• 5.3 Pipeline Segmentation by Mechanism of Action
  • 5.3.1 Complement Inhibitors
  • 5.3.2 Anti-CD19 Therapies
  • 5.3.3 IL-6 Receptor Inhibitors
  • 5.3.4 FcRn Inhibitors
  • 5.3.5 CAR-T Cell Therapies
  • 5.3.6 Other Novel Immunotherapies
• 5.4 Pipeline Segmentation by Modality
  • 5.4.1 Monoclonal Antibodies
  • 5.4.2 Cell Therapies
  • 5.4.3 Recombinant Proteins
  • 5.4.4 Other Biologics
• 5.5 Clinical Trial Landscape
  • 5.5.1 Ongoing Trials
  • 5.5.2 Completed Trials
  • 5.5.3 Trial Design Trends
  • 5.5.4 Primary Endpoints Analysis
• 5.6 Innovation Trends
  • 5.6.1 Biomarker Development
  • 5.6.2 Precision Medicine Approaches
  • 5.6.3 Combination Therapy Strategies
  • 5.6.4 Next-Generation Biologics

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Attack Management
  • 6.2.1 Corticosteroids
  • 6.2.2 Plasma Exchange
  • 6.2.3 Intravenous Immunoglobulin
• 6.3 Maintenance Therapy
  • 6.3.1 Complement Inhibitors
  • 6.3.2 Anti-CD19 Therapies
  • 6.3.3 IL-6 Receptor Inhibitors
  • 6.3.4 Immunosuppressive Agents
• 6.4 Approved Therapies Comparison
  • 6.4.1 Efficacy Comparison
  • 6.4.2 Safety Comparison
  • 6.4.3 Relapse Prevention Outcomes
  • 6.4.4 Dosing and Administration Comparison
• 6.5 Treatment Guidelines and Clinical Practice Trends

7. Global Neuromyelitis Optica Emerging Therapies Report Size & Forecast

• 7.1 Global Market Size Analysis
• 7.2 Historical Market Assessment
• 7.3 Market Forecast
• 7.4 Revenue Forecast by Therapy Type
• 7.5 Revenue Forecast by Route of Administration
• 7.6 Revenue Forecast by Distribution Channel
• 7.7 Market Attractiveness Analysis

8. Global Neuromyelitis Optica Emerging Therapies Report Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Complement Inhibitors
  • 8.1.2 Anti-CD19 Therapies
  • 8.1.3 IL-6 Receptor Inhibitors
  • 8.1.4 Emerging Therapies
• 8.2 By Route of Administration
  • 8.2.1 Intravenous
  • 8.2.2 Subcutaneous
  • 8.2.3 Oral
• 8.3 By End User
  • 8.3.1 Hospitals
  • 8.3.2 Specialty Clinics
  • 8.3.3 Academic Medical Centers
• 8.4 By Distribution Channel
  • 8.4.1 Hospital Pharmacies
  • 8.4.2 Retail & Specialty Pharmacies
  • 8.4.3 Online Pharmacies

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement
  • 10.1.5 Key Companies and Products
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
• 11.3 Europe Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Orphan Drug Regulations
• 11.8 Fast Track and Accelerated Approval Pathways
• 11.9 Pharmacovigilance Requirements
• 11.10 Intellectual Property Landscape

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Pipeline Competitiveness Analysis
• 12.4 Strategic Collaborations
• 12.5 Licensing and Partnership Activities
• 12.6 Mergers and Acquisitions
• 12.7 SWOT Analysis
• 12.8 Porter's Five Forces Analysis

13. Company Profiles

• 13.1 Alexion Pharmaceuticals
  • 13.1.1 Company Overview
  • 13.1.2 Approved Drugs: Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)
  • 13.1.3 Key Indications
  • 13.1.4 NMOSD Commercial Strategy
  • 13.1.5 Recent Developments
• 13.2 Roche Holding AG
  • 13.2.1 Company Overview
  • 13.2.2 Approved Drug: Enspryng (satralizumab)
  • 13.2.3 Key Indications
  • 13.2.4 Commercial Strategy
  • 13.2.5 Recent Developments
• 13.3 Amgen Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Approved Drug: Uplizna (inebilizumab-cdon)
  • 13.3.3 Key Indications
  • 13.3.4 Commercial Strategy
  • 13.3.5 Recent Developments
• 13.4 argenx SE
  • 13.4.1 Company Overview
  • 13.4.2 Pipeline: Efgartigimod
  • 13.4.3 Mechanism of Action
  • 13.4.4 Clinical Development Status
  • 13.4.5 Strategic Initiatives
• 13.5 Dianthus Therapeutics, Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Pipeline: DNTH103
  • 13.5.3 Mechanism of Action
  • 13.5.4 Clinical Development Status
  • 13.5.5 Strategic Initiatives
• 13.6 HanAll Biopharma Co., Ltd.
  • 13.6.1 Company Overview
  • 13.6.2 Pipeline: Batoclimab
  • 13.6.3 Mechanism of Action
  • 13.6.4 Clinical Development Status
  • 13.6.5 Strategic Initiatives
• 13.7 Kyverna Therapeutics, Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Pipeline: KYV-101
  • 13.7.3 Mechanism of Action
  • 13.7.4 Clinical Development Status
  • 13.7.5 Strategic Initiatives
• 13.8 Chugai Pharmaceutical Co., Ltd.
  • 13.8.1 Company Overview
  • 13.8.2 Approved Drug: Enspryng (satralizumab) in Japan
  • 13.8.3 Key Indications
  • 13.8.4 Commercial Strategy
  • 13.8.5 Recent Developments
• 13.9 Viela Bio, Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Approved Drug: Uplizna (inebilizumab-cdon)
  • 13.9.3 Key Indications
  • 13.9.4 Commercial Strategy
  • 13.9.5 Historical Milestones
• 13.10 AstraZeneca PLC
  • 13.10.1 Company Overview
  • 13.10.2 NMOSD Portfolio Overview
  • 13.10.3 Approved Products and Lifecycle Management
  • 13.10.4 Commercial Strategy
  • 13.10.5 Recent Developments

14. Future Outlook

• 14.1 Market Growth Prospects
• 14.2 Future Treatment Paradigm
• 14.3 Emerging Technologies
• 14.4 Pipeline Success Probability
• 14.5 Competitive Outlook
• 14.6 Investment Opportunities
• 14.7 Strategic Recommendations

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Secondary Research Sources
• 15.4 Primary Research Approach
• 15.5 Data Validation and Triangulation
• 15.6 Forecasting Methodology
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations and Definitions